Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 5095

Original article / research
Year : 2017 | Month : March | Volume : 11 | Issue : 3 | Page : EC36 - EC39

Utility of Tru-Cut Biopsy of Breast Lesions - An Experience in a Regional Cancer Center of a Developing Country

Sagarika Samantaray, Niharika Panda, Kusumabati Besra, Lucy Pattanayak, Subrat Samantara, Sashibhusan Dash

1. Associate Professor, Department of Pathology, A.H. Regional Cancer Centre, Cuttack, Orissa, India. 2. Associate Professor, Department of Radiotherapy, A.H. Regional Cancer Centre, Cuttack, Orissa, India. 3. Associate Professor, Department of Pathology, A.H. Regional Cancer Centre, Cuttack, Orissa, India. 4. Assistant Professor, Department of Radiotherapy, A.H. Regional Cancer Centre, Cuttack, Orissa, India. 5. Assistant Professor, Department of Oncosurgery, A.H. Regional Cancer Centre, Cuttack, Orissa, India. 6. Associate Professor, Department of Pathology, A.H. Regional Cancer Centre, Cuttack, Orissa, India.

Correspondence Address :
Dr. Sagarika Samantaray,
Department of Pathology, A.H. Regional Cancer Centre, Cuttack-753007, Orissa, India.
E-mail: ssamantaray01@gmail.com

Abstract

Introduction: Tru-cut Needle Biopsy (TCB) is an integral part of triple assessment of breast cancer, which includes clinical assessment, mammography and TCB or Core Needle Biopsy (CNB). The technique is reliable, simple, and reproducible, and inexpensive, which can be adapted even for low-income group of patients and in developing countries.

Aim: This study was done to establish the efficacy of TCB of palpable breast lesions in a developing country where mammography is not possible in all cases.

Materials and Methods: A retrospective analysis of 892 TCBs was done in AH Regional Cancer Centre, Cuttack, Odisha, India where TCBs were performed in patients presenting to outpatient department with palpable breast lesions. The H&E stained sections were interpreted by pathologists of the same centre. Diagnosis was classified into different categories. Immunohistochemistry (IHC) for Estrogen Receptor (ER), Progesterone Receptor (PR) and Her-2/neu was done and interpreted by Allred scoring system.

Results: A total 892 TCBs were analysed with 23 repeat TCBs. There were 13 (1.4%) male patients. A total of 747 cases (83.6%) were diagnosed as malignant, including 735 carcinomas, nine malignant phyllodes tumour, two angiosarcoma and one case of Non-Hodgkin’ Lymphoma (NHL). It was possible to diagnose special histological types such as lobular carcinoma, metaplastic carcinoma and mucinous carcinoma on TCB. A total of 21 cases were diagnosed as carcinoma on repeat biopsy. Eight of the 735 TCBs diagnosed as carcinoma were bilateral breast cancers, hence actual number of carcinoma cases were 727. IHC was done successfully on the paraffin blocks in 260 cases. In this series out of 727 patients of carcinomas 30% were in young, i.e., below 40 years of age, including four cases of carcinoma below 20 years. There were no false positive case in this study giving a specificity of 100% and sensitivity was 97%.

Conclusion: TCBs are well tolerated by patients, can be done in OPDs and reduce cost. It is possible to give histological diagnosis of carcinoma, lymphoma, phyllodes tumour and sarcomas on TCBs. The paraffin blocks of TCBs can be used for IHC study which helps the oncologists for preoperative adjuvant therapy.

Keywords

Breast carcinoma, Core biopsy, Immunohistochemistry, Phyllodes tumour

How to cite this article :

Sagarika Samantaray, Niharika Panda, Kusumabati Besra, Lucy Pattanayak, Subrat Samantara, Sashibhusan Dash. UTILITY OF TRU-CUT BIOPSY OF BREAST LESIONS - AN EXPERIENCE IN A REGIONAL CANCER CENTER OF A DEVELOPING COUNTRY. Journal of Clinical and Diagnostic Research [serial online] 2017 March [cited: 2017 Mar 27 ]; 11:EC36-EC39. Available from
http://jcdr.net/back_issues.asp?issn=0973-709x&year=2017&month=March&volume=11&issue=3&page=EC36-EC39&id=9548

DOI and Others

DOI: 10.7860/JCDR/2017/23572.9548



Date of Submission: Aug 19, 2016
Date of Peer Review: Sep 20, 2016
Date of Acceptance: Nov 28, 2016
Date of Publishing: Mar 01, 2017


Financial OR OTHER COMPETING INTERESTS: None.

JCDR is now Monthly and more widely Indexed .
  • PubMed Central® (PMC)New
  • Academic Search Complete Database
  • Chemical Abstracts Service
  • Directory of Open Access Journals (DOAJ)
  • EBSCOhostNew
  • Embase & EMbiology
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Open J-Gate
  • Popline (reproductive health literature)
  • SCOPUS
  • www.omnimedicalsearch.com